New drug aims to keep brain tumors at bay after standard therapy

NCT ID NCT06809322

Recruiting now Disease control Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 5 times

Summary

This phase 3 trial tests whether the drug vorasidenib can delay tumor progression in people with IDH-mutant grade 2 or 3 astrocytoma after they finish initial chemoradiotherapy. About 468 participants will receive either vorasidenib or a placebo daily. The main goal is to see if vorasidenib extends the time before the tumor grows back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vorasidenib
What this could lead to: If successful, vorasidenib could delay tumor regrowth after standard treatment, giving people with this brain cancer more time without progression.
What could go wrong: This is a phase 3 trial, but results are not yet known. The drug may not improve outcomes over placebo, and side effects could occur. It is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, CNS5 WHO GRADE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) astrocytoma, IDH-mutant, grade 2 astrocytoma, IDH-mutant, grade 3

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA

Contacts and locations

Locations

AOU Citta della Salute e della Scienza di Torino
RECRUITING

Torino, Italy
Academisch Ziekenhuis Maastricht
RECRUITING

Maastricht, Netherlands
Amsterdam UMC location VUMC
RECRUITING

Amsterdam, Netherlands
Assistance Publique Hopitaux de Paris APHP - Sorbonne
RECRUITING

Paris, France
Bellaria Hospital, IRCCS Istituto delle Scienze Neurologiche - AUSL di Bologna
RECRUITING

Bologna, Italy
CHU Lyon - Hopital neurologique Pierre Wertheimer
RECRUITING

Lyon, France
Clatterbridge Cancer Centre
NOT_YET_RECRUITING

Metropolitan Borough of Wirral, United Kingdom
Erasmus MC
RECRUITING

Rotterdam, Netherlands
Ghent University Hospital
RECRUITING

Ghent, Belgium
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, Spain
Hospital de Sant Pau i La Santa Creu
RECRUITING

Barcelona, Spain
Kepler University Hospital - Neuromed campus
RECRUITING

Linz, Austria
Mannheim University Hospital
RECRUITING

Mannheim, Germany
Marseille APHM
RECRUITING

Marseille, France
Masaryk Memorial Cancer Institute
RECRUITING

Brno, Czechia
Medical University of Innsbruck
RECRUITING

Innsbruck, Austria
Medical University of Vienna
RECRUITING

Vienna, Austria
NNeurology department heidelberg
RECRUITING

Heidelberg, Germany
Oncopole Claudius Regaud, IUCT-Oncopole
RECRUITING

Toulouse, France
Queen Elizabeth Hospital Birmingham
NOT_YET_RECRUITING

Birmingham, United Kingdom
Royal Marsden Hospital
NOT_YET_RECRUITING

Surrey Quays, United Kingdom
Sapienza University
NOT_YET_RECRUITING

Roma, Italy
The Christie NHS Foundation Trust
NOT_YET_RECRUITING

Manchester, United Kingdom
U.Z. Leuven - Campus Gasthuisberg
RECRUITING

Leuven, Belgium
Universitaetsklinikum Regensburg
RECRUITING

Regensburg, Germany
Universitair Ziekenhuis Brussel
RECRUITING

Brussels, Belgium
Universitary hospital Bordeaux France
RECRUITING

Bordeaux, France
Universitaskliniken Bonn
RECRUITING

Bonn, Germany
University Hospital Basel
NOT_YET_RECRUITING

Basel, Switzerland
University Hospital Frankfurt -Senckenberg Institute of Neurooncology
RECRUITING

Frankfurt, Germany
University Hospital Zurich
RECRUITING

Zurich, Switzerland
Vall de Hebron Hospital
RECRUITING

Barcelona, Spain
Veneto Institute of Oncology
NOT_YET_RECRUITING

Padova, Italy